Analysis of Fas ligand gene mutation in patients with systemic lupus erythematosus

Arthritis and Rheumatism

Volumn 43, Issue 1, 2000, Pages 135-139

  Kojima, Takeshi ^a   Horiuchi, Takahiko ^a,c   Nishizaka, Hiroaki ^a   Sawabe, Takuya ^a   Higuchi, Masanori ^a   Harashima, Shin Ichi ^a   Yoshizawa, Shigeru ^a   Tsukamoto, Hiroshi ^a   Nagasawa, Kohei ^b   Niho, Yoshiyuki ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b SAGA UNIVERSITY   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FAS LIGAND;

ARTICLE; CONTROLLED STUDY; GENE AMPLIFICATION; GENETIC POLYMORPHISM; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; PATHOGENESIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYSTEMIC LUPUS ERYTHEMATOSUS;

DNA MUTATIONAL ANALYSIS; DNA PRIMERS; EXONS; FAS LIGAND PROTEIN; FEMALE; GENETIC SCREENING; HUMANS; INTRONS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MEMBRANE GLYCOPROTEINS; MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; RNA, MESSENGER;

EID: 0034046228     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(200001)43:1<135::AID-ANR17>3.0.CO;2-Q     Document Type: Article

References (15)

1. Kotzin BL. Systemic lupus erythematosus. Cell 1996;85:303-6.
2. Nagata S, Suda T. Fas and Fas ligand: lpr and gld mutations. Immunol Today 1995;16:39-43.
3. Cheng J, Zhou T, Changdan L, Shapiro JP, Brauer MJ, Kiefer MC, et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 1994;263:1759-62.
4. Horiuchi T, Nishizaka H, Yasunaga S, Higuchi M, Tsukamoto H, Hayashi K, et al. Association of Fas/APO-1 gene polymorphism with systemic lupus erythematosus in Japanese. Rheumatology 1999;38:516-20.
5. Wu J, Wilson J, He J, Xiang L, Schur PH, Mountz JD. Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease. J Clin Invest 1996;98:1107-13.
6. Suzuki N, Ichino M, Mihara S, Kaneko S, Sakane T. Inhibition of Fas/Fas ligand-mediated apoptotic cell death of lymphocytes in vitro by circulating anti-Fas ligand autoantibodies in patients with systemic lupus erythematosus. Arthritis Rheum 1998;41:344-53.
7. Mehrian R, Quismorio FP Jr, Strassmann G, Stimmler MM, Horwitz DA, Kitridou RC, et al. Synergistic effect between interleukin-10 and bcl-2 genotypes in determining susceptibility to systemic lupus erythematosus. Arthritis Rheum 1998;41:596-602.
8. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
9. Horiuchi T, Macon KJ, Kidd VJ, Volanakis JE. Translational regulation of complement protein C2 expression by differential utilization of the 5′-untranslated region of mRNA. J Biol Chem 1990;265:6521-4.
10. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand: a novel member of the tumor necrosis factor family. Cell 1993;75:935-46.
11. Takahashi T, Tanaka M, Inazawa J, Abe T, Suda T, Nagata S. Human Fas ligand: gene structure, chromosome location and species specificity. Int Immunol 1994;6:1567-74.
12. McNally J, Yoo D-H, Drappa J, Chu J-H, Yagita H, Friedman SM, et al. Fas ligand expression and function in systemic lupus erythematosus. J Immunol 1997;159:4628-36.
13. Kayagaki N, Yamaguchi N, Nagao F, Matsuo S, Maeda H, Okumura K, et al. Polymorphism of murine Fas ligand that affects the biological activity. Proc Natl Acad Sci U S A 1998;94:3914-9.
14. Hayashi, K. PCR-SSCP: a simple and sensitive method for detection of mutations in the genomic DNA. Genome Res 1991;1:34-8.
15. Cantwell MJ, Hua T, Zvaifler NJ, Kipps TJ. Deficient Fas ligand expression by synovial lymphocytes from patients with rheumatoid arthritis. Arthritis Rheum 1997;40:1644-52.